Ziglim-MV 2 Tablet is a combination oral antidiabetic medication containing Glimepiride 2mg, Metformin 500mg, and Voglibose 0.2mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to enhance insulin secretion, thereby lowering blood glucose levels. Metformin, a biguanide, primarily acts by reducing hepatic glucose production and improving peripheral insulin sensitivity, contributing to better glycemic control. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, preventing postprandial hyperglycemia. The synergistic action of these three agents addresses multiple pathophysiological defects in type 2 diabetes, offering improved glycemic regulation. Ziglim-MV 2 is prescribed as part of a comprehensive diabetes management plan including diet and exercise. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and hypersensitivity to any component. Caution is advised in patients with cardiovascular disease, and regular monitoring of blood glucose and renal function is recommended. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, and rarely, lactic acidosis. This combination therapy should be used under medical supervision to optimize therapeutic outcomes and minimize risks.